St. Paul, Minn.-based Kindeva is set to use its product development, regulatory affairs and manufacturing capabilities to help develop and commercialize CHI’s αeolus dry-powder inhaler (DPI) platform technology, according to a news release.
Under the agreement, Kindeva will lead business development and product development activities, including toxicology, process development, and clinical design. CHI is slated to lead technology and device development, with both companies expecting the collaboration to lead to the development of multiple commercial products.
The companies will evaluate a range of drugs for the platform to inform development programs undertaken in partnership with biopharmaceutical companies. The initial drugs under evaluation could become products to treat a range of respiratory diseases, while the DPI platform could be used for the systemic delivery of drugs to the lungs to address even more conditions.
United Kingdom-based CHI’s αeolus technology platform is designed to produce greater delivery efficiency and consistency that is independent of patient effort, potentially leading to dose sparing.
“With their unrivalled history and expertise in inhaled drug-delivery, Kindeva is the ideal partner to bring this revolutionary technology to the market,” CHI co-founder & CTO David Harris said in the release. “We’re excited to be working together to bring pharmaceutical customers’ products to market faster and at significantly reduced risk, and to offer the unique opportunity to deliver therapies beyond the reach of existing inhalation technology. We’re looking forward to redefining what inhalers can achieve.”
“We are excited to partner with CHI to develop and commercialize a truly novel DPI technology platform,” added Kindeva CEO Aaron Mann. “As leaders in inhalation product development, Kindeva understands that the industry must embrace the development of patient-centered technologies in order to meaningfully improve the way patients are treated.
“The αeolus technology is designed to avoid many of the drawbacks of existing inhalation technology, addressing the need for efficiency, simplicity, and consistency of delivery, which lead to a more robust patient experience.”